PH12018502421A1 - Atropine-containing aqueous composition - Google Patents

Atropine-containing aqueous composition

Info

Publication number
PH12018502421A1
PH12018502421A1 PH12018502421A PH12018502421A PH12018502421A1 PH 12018502421 A1 PH12018502421 A1 PH 12018502421A1 PH 12018502421 A PH12018502421 A PH 12018502421A PH 12018502421 A PH12018502421 A PH 12018502421A PH 12018502421 A1 PH12018502421 A1 PH 12018502421A1
Authority
PH
Philippines
Prior art keywords
buffer
atropine
aqueous composition
containing aqueous
pcnt
Prior art date
Application number
PH12018502421A
Other languages
English (en)
Inventor
Donald Tan
Roger Beuerman
Hiroyuki Asada
Kyohei Takahashi
Koji Sakanaka
Takashi Morimoto
Toyomi Fujisawa
Original Assignee
Univ Nanyang Tech
Singapore Health Serv Pte Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60411416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12018502421(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Nanyang Tech, Singapore Health Serv Pte Ltd, Santen Pharmaceutical Co Ltd filed Critical Univ Nanyang Tech
Publication of PH12018502421A1 publication Critical patent/PH12018502421A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
PH12018502421A 2016-05-25 2018-11-16 Atropine-containing aqueous composition PH12018502421A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201604200P 2016-05-25
PCT/JP2017/019423 WO2017204262A1 (en) 2016-05-25 2017-05-24 Atropine-containing aqueous composition

Publications (1)

Publication Number Publication Date
PH12018502421A1 true PH12018502421A1 (en) 2019-09-30

Family

ID=60411416

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502421A PH12018502421A1 (en) 2016-05-25 2018-11-16 Atropine-containing aqueous composition

Country Status (15)

Country Link
US (2) US20210267885A1 (2)
EP (2) EP4112055A1 (2)
JP (6) JP6590860B2 (2)
KR (4) KR102580933B1 (2)
CN (3) CN117205209A (2)
AR (1) AR108591A1 (2)
CA (1) CA3023149C (2)
EA (1) EA201892703A1 (2)
ES (1) ES2929368T3 (2)
MY (1) MY189774A (2)
PH (1) PH12018502421A1 (2)
SG (1) SG11201809822SA (2)
TW (3) TWI874894B (2)
UA (1) UA126195C2 (2)
WO (1) WO2017204262A1 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
PH12019501945B1 (en) * 2017-02-21 2024-02-21 Singapore Health Serv Pte Ltd Composition and method for preventing or delaying onset of myopia comprising atropine
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
CN110934869B (zh) * 2018-09-25 2023-07-04 沈阳兴齐眼药股份有限公司 一种阿托品药物组合物和药盒产品
CN114533652B (zh) * 2018-09-25 2024-12-13 沈阳兴齐眼药股份有限公司 药物组合物、其制备方法和用途
PT3701938T (pt) 2019-03-01 2024-01-31 Medivis S R L Formulações oftálmicas à base de atropina
CN114302726A (zh) 2020-08-04 2022-04-08 参天制药株式会社 用于治疗近视、预防近视及/或抑制近视发展的药剂
WO2022080397A1 (ja) * 2020-10-14 2022-04-21 参天製薬株式会社 安定な医薬組成物
WO2022094409A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
WO2022130337A1 (en) * 2020-12-17 2022-06-23 Sun Pharmaceutical Industries Limited An aqueous sterile solution of atropine for ophthalmic use
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
US20230120997A1 (en) * 2021-10-18 2023-04-20 Ocular Science, Inc. Compositions and methods for myopia control and orthokeratology lenses treatment
CN114129511A (zh) * 2021-12-07 2022-03-04 河南润弘制药股份有限公司 一种具有改进稳定性的硫酸阿托品注射液
US12527739B2 (en) * 2022-09-11 2026-01-20 Alcon Inc. Aqueous pharmaceutical compositions comprising benzyl atropine and uses thereof
JP7665073B1 (ja) 2024-04-05 2025-04-18 ロート製薬株式会社 容器に収容してなる眼科用組成物
JP7723851B1 (ja) * 2024-11-22 2025-08-14 参天製薬株式会社 アトロピン含有水性医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
JP3166002B2 (ja) * 1997-01-27 2001-05-14 日本車輌製造株式会社 自動車の洗浄装置
US20030096831A1 (en) 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
EP1397132A4 (en) * 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
EP2152255A1 (en) * 2007-05-21 2010-02-17 Neuroptix Corporation Ophthalmic formulations of amyloid- contrast agents and methods of use thereof
CN101327216A (zh) * 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
JP2017102939A (ja) * 2016-12-26 2017-06-08 株式会社プロフィールド オーサリング装置、オーサリング方法、およびプログラム
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions

Also Published As

Publication number Publication date
JP7224390B2 (ja) 2023-02-17
TW202325296A (zh) 2023-07-01
TWI791438B (zh) 2023-02-11
TWI874894B (zh) 2025-03-01
TW202206070A (zh) 2022-02-16
CN109310687B (zh) 2023-10-20
US20240307305A1 (en) 2024-09-19
SG11201809822SA (en) 2018-12-28
KR102804061B1 (ko) 2025-05-07
ES2929368T3 (es) 2022-11-28
AR108591A1 (es) 2018-09-05
JP2020007356A (ja) 2020-01-16
CA3023149A1 (en) 2017-11-30
TW201808289A (zh) 2018-03-16
JP2021120404A (ja) 2021-08-19
KR20230141882A (ko) 2023-10-10
JP6886502B2 (ja) 2021-06-16
KR20250067951A (ko) 2025-05-15
CA3023149C (en) 2024-07-02
CN117205210A (zh) 2023-12-12
TWI849355B (zh) 2024-07-21
JP2025084921A (ja) 2025-06-03
MY189774A (en) 2022-03-04
EP3463360B1 (en) 2022-08-31
JP2018021007A (ja) 2018-02-08
EA201892703A1 (ru) 2019-04-30
JP6590860B2 (ja) 2019-10-16
JP2023058574A (ja) 2023-04-25
EP3463360A4 (en) 2020-01-29
CN109310687A (zh) 2019-02-05
KR20220154842A (ko) 2022-11-22
EP4112055A1 (en) 2023-01-04
WO2017204262A1 (en) 2017-11-30
UA126195C2 (uk) 2022-08-31
US20210267885A1 (en) 2021-09-02
CN117205209A (zh) 2023-12-12
KR102580933B1 (ko) 2023-09-19
KR20190013877A (ko) 2019-02-11
EP3463360A1 (en) 2019-04-10
JP2025176149A (ja) 2025-12-03

Similar Documents

Publication Publication Date Title
PH12018502421A1 (en) Atropine-containing aqueous composition
MX2022012110A (es) Sistemas crispr clase ii tipo ii.
WO2019014395A8 (en) GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
WO2018176055A3 (en) High level in vivo biosynthesis and isolation of water-soluble cannabinoids in plant systems
WO2019053661A3 (en) GALNAC DERIVATIVES
WO2018175636A3 (en) Compositions and methods for immunooncology
WO2018094356A3 (en) Compositions and methods for target nucleic acid modification
MX2017008937A (es) Carbonato de calcio tratado en la superficie con estabilidad mejorada en ambientes con un ph de 4.5 a 7.
MA39462A1 (fr) Nouvel activateur de sol contenant du lignosulfonate d'ammonium, et ses utilisations
PH12017500286A1 (en) Lithium-containing calcium aluminate phosphate cement admixtures
EP4656715A3 (en) Suspension composition for hematology analysis control
WO2017165412A3 (en) T-cell exhaustion state-specific gene expression regulators and uses thereof
WO2018146557A3 (en) Long double-stranded rna for rna interference
AU2018275786A1 (en) Method for dispersing kinetic hydrate inhibitors
MX2020013732A (es) Metodos de fabricacion de composiciones de aminoacidos.
WO2019013532A3 (ko) 아세토하이드록시산 신타아제 변이체, 이를 포함하는 미생물 또는 이를 이용하는 l-분지쇄 아미노산 생산 방법
EP4696364A3 (en) A system for planning and/or providing neuromodulation
WO2017223261A3 (en) Hydrogels, articles comprising hydrogels, and methods thereof
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
WO2016108044A3 (en) Substrates having a functional capability
WO2017181163A3 (en) Methods and compositions for detection and diagnosis of breast cancer
MX2019003669A (es) Composiciones para el cuidado del cabello que comprenden copolimeros de glicerido.
PH12016502386B1 (en) Oral care compositions
PH12018502286A1 (en) Rt-pcr-hrm or pcr-hrm primer, reagent and method for rapidly distinguishing four serotypes of dengue virus